Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Jun 18;83(24):2472-2486.
doi: 10.1016/j.jacc.2024.03.400. Epub 2024 Apr 7.

Artificial Intelligence for Cardiovascular Care-Part 1: Advances: JACC Review Topic of the Week

Pierre Elias  1 , Sneha S Jain  2 , Timothy Poterucha  3 , Michael Randazzo  4 , Francisco Lopez Jimenez  5 , Rohan Khera  6 , Marco Perez  2 , David Ouyang  7 , James Pirruccello  8 , Michael Salerno  2 , Andrew J Einstein  3 , Robert Avram  9 , Geoffrey H Tison  8 , Girish Nadkarni  10 , Vivek Natarajan  11 , Emma Pierson  12 , Ashley Beecy  13 , Deepa Kumaraiah  14 , Chris Haggerty  15 , Jennifer N Avari Silva  16 , Thomas M Maddox  17
Affiliations
Free article
Review

Artificial Intelligence for Cardiovascular Care-Part 1: Advances: JACC Review Topic of the Week

Pierre Elias et al. J Am Coll Cardiol. .
Free article

Abstract

Recent artificial intelligence (AI) advancements in cardiovascular care offer potential enhancements in diagnosis, treatment, and outcomes. Innovations to date focus on automating measurements, enhancing image quality, and detecting diseases using novel methods. Applications span wearables, electrocardiograms, echocardiography, angiography, genetics, and more. AI models detect diseases from electrocardiograms at accuracy not previously achieved by technology or human experts, including reduced ejection fraction, valvular heart disease, and other cardiomyopathies. However, AI's unique characteristics necessitate rigorous validation by addressing training methods, real-world efficacy, equity concerns, and long-term reliability. Despite an exponentially growing number of studies in cardiovascular AI, trials showing improvement in outcomes remain lacking. A number are currently underway. Embracing this rapidly evolving technology while setting a high evaluation benchmark will be crucial for cardiology to leverage AI to enhance patient care and the provider experience.

Keywords: artificial intelligence; cardiac imaging; deep learning; digital health; innovation; large language models; machine learning.

PubMed Disclaimer

Conflict of interest statement

Funding Support and Author Disclosures Dr Elias has research support provided to his institution from Eidos Therapeutics, Pfizer, Janssen, Edwards Lifesciences, New York Academy of Medicine, and Google. Dr Jain has consulting relationships with Bristol Myers Squibb, ARTIS Ventures, and Broadview Ventures. Dr Poterucha owns stock in Abbott Laboratories and Baxter International; and research support is provided to his institution from the Amyloidosis Foundation, American Heart Association (Award #933452 and #23SCISA1077494), Eidos Therapeutics, Pfizer, Janssen, Edwards Lifesciences, and the Glorney-Raisbeck Fellowship Award from the New York Academy of Medicine. Dr Avram is a co-inventor in the patent 63/208,406 (Method and System for Automated Analysis of Coronary Angiograms); and has received speaker fees from Abbott, Boston Scientific, Boehringer Ingelheim, and Novartis. Dr Avari Silva is the co-founder and consultant to and holds equity in SentiAR; the technology has been licensed by Washington University to SentiAR. Dr Maddox has received grant funding from the National Institutes of Health (NHLBI UG3HL165065: The Rhythm Evaluation for Anticoagulation with Continuous Monitoring of Atrial Fibrillation Trial [REACT-AF]); has received honoraria and/or expense reimbursement in the past 3 years from the University of Chicago, George Washington University, Baylor College of Medicine, the New York Cardiological Society, and Medscape (Dec 2022); has received compensation and travel expense reimbursement for American College of Cardiology leadership roles and meetings; is currently employed as a cardiologist and Vice President, Digital Products and Innovation at BJC HealthCare/Washington University School of Medicine, and in this capacity, he is advising Myia Labs, for which his employer is receiving equity compensation in the company, he is receiving no individual compensation from the company, and he is a compensated director for a New Mexico-based foundation, the J.F Maddox Foundation. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

LinkOut - more resources